Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$10.7 million.

  • RxSight's Net Cash Flow fell 3865.75% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 8888.08%. This contributed to the annual value of $7.1 million for FY2024, which is 42129.21% up from last year.
  • According to the latest figures from Q3 2025, RxSight's Net Cash Flow is -$10.7 million, which was down 3865.75% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Net Cash Flow ranged from a high of $29.6 million in Q2 2022 and a low of -$43.7 million during Q4 2021
  • Moreover, its 5-year median value for Net Cash Flow was $36000.0 (2024), whereas its average is $838473.7.
  • Data for RxSight's Net Cash Flow shows a peak YoY increase of 550753.56% (in 2021) and a maximum YoY decrease of 285482.65% (in 2021) over the last 5 years.
  • Over the past 5 years, RxSight's Net Cash Flow (Quarter) stood at -$43.7 million in 2021, then skyrocketed by 106.55% to $2.9 million in 2022, then crashed by 106.05% to -$173000.0 in 2023, then soared by 120.81% to $36000.0 in 2024, then crashed by 29880.56% to -$10.7 million in 2025.
  • Its last three reported values are -$10.7 million in Q3 2025, $12.3 million for Q2 2025, and $11.3 million during Q1 2025.